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Many patients with proteinuric chronic nephropathies
progress inexorably to end-stage renal failure (ESRF),
which is usually associated with the histologic findings
of glomerulosclerosis and interstitial fibrosis [1]. In the
last two decades clarification of the mechanisms of in-
jury underlying the progression of chronic proteinuric
nephropathies has been a major challenge for the re-
nal community. Experimental renal ablation in the rat
was instrumental in clarifying the pathophysiology of re-
nal adaptation to nephron loss [2]. After removal of a
critical portion of renal mass, remnant intact nephrons
undergo sudden hypertrophy with concomitant lowering
of arteriolar resistance and increased glomerular plasma
flow. Because the tone of afferent arterioles drops more
than the efferent ones, glomerular capillary hydraulic
pressure rises, and more filtrate is formed per nephron.
While such changes serve to enhance the filtration capac-
ity of remaining nephron units, thus minimizing the func-
tional consequences of nephron loss, they are ultimately
detrimental.
Indeed, the high intraglomerular capillary pressure en-
larges the radii of the pores perforating the glomerular
capillary barrier by a mechanism at least partly mediated
by angiotensin (Ang) II. This impairs the size-selective
function of the barrier and causes protein ultrafiltra-
tion. An excess of proteins in the lumen of the proximal
tubules, and the secondary process of tubular epithelial
endocytosis may exert a nephritogenic effect.
Analysis of renal biopsy specimens from rats with
doxorubicin-induced nephrosis [3] or age-related pro-
teinuria [4] showed the accumulation of filtered proteins
in the cytoplasm of proximal tubular cells, associated
with interstitial inflammatory reactions and tubuloint-
erstitial fibrotic and glomerulosclerotic lesions. Several
other studies in rat models revealed a close link between
abnormal permeability of the glomerular capillary bar-
rier to proteins and the subsequent renal structural in-
jury. Examples are streptozotocin-induced diabetes, the
C© 2005 by the International Society of Nephrology
BioBreeding/Worchester (BB/w) rat, the spontaneous
nephropathy of Zucker rats, and the passive Heymann
nephritis rats [5, 6].
CONSISTENCY BETWEEN ALBUMIN
CONCENTRATIONS USED IN VITRO AND IN
VIVO EXPOSURE OF PROXIMAL TUBULAR
CELLS IN PROTEINURIC NEPHROPATHIES
In vitro studies [7] in the last few years have indeed
confirmed that proximal tubular cells can actually change
their phenotype in response to protein overload [8]. Nev-
ertheless, some investigators raised doubts about the pos-
sibility to transfer this in vitro evidence to the in vivo
proteinuric conditions in animals, arguing that too high
concentrations of albumin were used in vitro to challenge
proximal tubular cells in culture. Fractional micropunc-
ture studies in normal rats [9] allowed the glomerular
filtered albumin concentrations to be estimated by ex-
trapolating the tubular fluid-to-plasma inulin concentra-
tion ratio into one. These experiments have documented
that filtered albumin reached the luminal side of prox-
imal tubular cells at the concentration of 0.023 mg/mL.
Albumin was almost evenly reabsorbed in early and late
proximal convoluted and straight tubules, so that dis-
tally the concentration of this protein was negligible. In
rats with renal mass ablation, a model of proteinuric re-
nal disease, daily urinary protein excretion may exceed
600 mg/24h. Assuming an average GFR of 1.5 mL/min,
a protein concentration of 0.27 mg/mL is expected at
the early proximal convoluted tubules. Considering that
along this nephron segment one third of filtered wa-
ter, but fewer proteins, is reabsorbed [10], the ultimate
protein concentration detected at the straight portion of
proximal convoluted tubules should be close to 1 mg/mL.
Approximately, the latter is the albumin concentration
used to activate in vitro proximal tubular cells in cul-
ture. Together, these observations suggest that, actually,
proteinuric renal diseases in animal models and in vitro
experimental settings share similarity as far as the ex-
posure of proximal tubular cells to albumin overload. A
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further critical point to be considered, however, is the
duration of exposure of tubular cells to proteins, which
influences both the activation in vitro and the develop-
ment of tubulointerstitial injury in vivo. Thus, in rats with
adriamycin nephrosis, a severe model of nephrotic pro-
teinuria that invariably progresses to tubulointerstitial
damage and glomerulosclerosis, in renal biopsies taken
one month after the onset of nephrotic proteinuria, only
mild glomerular changes without evidence of interstitial
inflammation were found [11]. On the other hand, find-
ings that biopsy specimens—collected from these animals
more than six months after the onset of proteinuria—
showed frank glomerular and tubulointerstitial damage
[11] give a precise indication of the time necessary to de-
velop inflammatory lesions and subsequent sclerosis in
the setting of high protein excretion rate. This implies
that in vivo, proximal tubular cells have processed a huge
amount of proteins over a period of months before tubu-
lointerstitial injury did manifest. This makes difficult a
direct comparison between a temporary in vitro experi-
ment and long-term in vivo condition as far as exposure
to proteins of tubular cells. Indeed, the variable to take
into account is not only the protein concentration at a
given time point (as in vitro culture), but also the time
of exposure to a given protein concentration (as in vivo)
that ultimately provides the actual total amount of stim-
ulatory proteins handled by the cells. Nevertheless, it is
quite evident that in the in vivo setting the total amount
of proteins processed by the cells far exceeds that of cul-
tured tubular cells, even after exposure to protein con-
centrations higher than 10 mg/mL for the few days of the
culture.
ABNORMAL PROTEIN TUBULAR
REABSORPTION ACTIVATES LOCAL
HORMONES, INFLAMMATORY CHEMOKINES,
AND TUBULOINTERSTITIAL INJURY
In proximal tubular cells in culture exposed to in-
creasing concentrations of delipidated albumin, IgG, or
transferrin, the rate of synthesis of endothelin-1 (ET-1)
enhanced several times in a concentration-dependent
fashion. Similarly, albumin and transferrin up-regulated
monocyte chemoattractant protein (MCP-1) gene, an
event abrogated by lysine, which inhibits luminal uptake,
and by actinomycin D, which limits gene transcription.
Very similar findings were reported for albumin-induced
up-regulation of RANTES (Regulated upon Activation,
Normal T cell Expressed and Secreted), an immunoreg-
ulatory cytokine with chemotactic properties for mono-
cytes and memory T cells in proximal tubular cells in
culture [12]. Albumin is also a strong stimulus for tubular
IL-8 expression, which occurs via nuclear factor (NF)-
kappaB-dependent pathways [13]. Interestingly, in cul-
tured cells, the secretion of newly synthesized ET-1,
MCP-1, and RANTES, PDGF-AB [14], was mainly po-
larized toward the basolateral compartment in response
to protein overloading. If a similar pattern of secretion
occurs in vivo in response to protein over-reabsorption,
these substances are released into the interstitium to gen-
erate chemokine gradients at the cell basolateral face,
promote macrophage and T lymphocyte migration [15],
and induce fibroblasts to proliferate and ultimately in-
crease extracellular matrix protein synthesis. Consistent
with these in vitro studies, in rat models of proteinuric
renal disease, expression of renal genes encoding vasoac-
tive and proinflammatory molecules was consistently up-
regulated, and synthesis of the corresponding peptides
was enhanced in renal tissue, particularly at proximal
tubular level. This was positively related to the degree
of proteinuria [5, 16].
Among processes underlying interstitial damage in
proteinuric conditions, the activation of complement pro-
teins in the proximal tubule has major proinflammatory
potential. On this line, a recent review has highlighted the
possible therapeutic role of complement inhibitors in pro-
teinuric progressive nephropathies [17]. Intracellular C3
staining was detected in proximal tubules of proteinuric
rats with remnant kidneys early after 5/6 nephrectomy,
and preceded the appearance of inflammation. C3 colo-
calized with IgG to the same tubular cells [18]. Induction
of tubular C3 during protein overload has also been re-
ported [19]. Of great interest is the observation that local
synthesis of C3 may stimulate transmigration of T cells
across tubular epithelial cells, a process that involves di-
rect action of tissue C3 with infiltrating T cells expressing
C3 receptors [20].
Excessive protein reabsorption by proximal tubu-
lar cells promotes fibrogenesis by favoring release of
chemoattractants, which, in turn, foster local recruitment
of mononuclear cells. Interstitial accumulation of inflam-
matory cells via release of transforming growth factor
(TGF)-b , platelet-derived growth factor (PDGF), and
other cytokines leads to interstitial cell transformation
into myofibroblasts. In addition, proximal tubular epithe-
lial cells interact with surrounding interstitial fibroblasts
to promote fibrogenesis via paracrine release of profibro-
genic molecules such as TGF-b , PDGF, and endothelin-1
[21].
DO MANEUVERS THAT LIMIT PROTEIN
TRAFFIC OR ITS CONSEQUENCES PREVENT
RENAL DISEASE PROGRESSION IN ANIMAL
MODELS?
If the interstitial inflammatory reaction and the conse-
quent fibrosis in chronic proteinuric nephropathies were
indeed a feature of protein overloading, limiting protein
traffic or the biological effect of excessive tubular pro-
tein reabsorption should prevent or retard renal disease
progression. This is precisely what happens in animals
given low-protein diets or undergoing pharmacologic
Perico et al: Pathophysiology of disease progression in proteinuric nephropathies S-81
manipulation with renin-angiotensin system (RAS)
blockers. In rats with renal mass ablation, as well as
in animals with experimental diabetes and adriamycin
nephropathy, a low-protein diet, by restoring the size-
selective properties of the glomerular barrier, prevented
proteinuria and renal injury [22]. Angiotensin-converting
enzyme (ACE) inhibitors were also found to reduce
urinary protein excretion and subsequent renal lesions
in aging rats [23]. In experimental diabetes, short- or
long-term treatment with enalapril or the angiotensin II
receptor blocker losartan reduced proteinuria and con-
ferred protection [22, 24]. ACE inhibitors reduced pro-
teinuria and limited progressive deterioration of renal
function in other models of renal disease progression,
including spontaneous proteinuria in male MWF/Ztm
rats and passive Heymann nephritis [25]. There is evi-
dence to suggest that antiproteinuric drugs act by reduc-
ing the mean dimensions of large unselective pores of
the glomerular capillary wall, thus ameliorating the size-
selective function of the barrier to macromolecules. In
rats with renal mass ablation or streptozotocin-induced
diabetes, blocking the ET-1 receptor with a specific an-
tagonist prevented renal structural damage. On the same
line, in rats with puromycin nephrosis, the treatment with
neutralizing anti-MCP-1 antibody effectively attenuated
the extent of renal interstitial macrophage infiltration
[26]. Moreover, the secondary interstitial accumulation
of monocytes and T lymphocytes in mice with crescentic
glomerulonephritis was effectively limited by the selec-
tive receptor antagonist MetRANTES [27, 28]. In addi-
tion, the combined therapy with an ACE inhibitor and
mycophenolate mofetil—an immunosuppressive agent
that inhibits T-cell proliferation and adhesion molecule
expression—limited proteinuria and the interstitial accu-
mulation of T lymphocytes and monocytes/macrophages
and renal structural lesions more effectively than ACE
inhibitor alone [29]. In a recent study performed in rats
with Heymann nephritis and heavy proteinuria, contem-
porary blocking of angiotensin II and ET-1 activity by
an ACE inhibitor associated with a ETA receptor an-
tagonist was more renoprotective than each drug alone
[30]. Moreover, experimental evidence is becoming avail-
able, which indicates that anti-TGF-b antibody added on
a background of chronic angiotensin-converting enzyme
inhibition fully normalized proteinuria and prevented re-
nal injury of diabetic nephropathy [31]. Thus, limiting
protein excretion and the consequent activation of tubu-
lar epithelial cells are instrumental in protecting the kid-
ney from further damage in animals.
PROTEINURIA IS A RISK MARKER FOR
PROGRESSIVE RENAL FUNCTION LOSS IN
HUMANS
Proteinuria has long been known to be a marker of the
severity of kidney disease [32]. The prevailing opinion,
however, was that proteinuria was primarily a marker of
renal injury, and that the more the kidney was damaged,
the more it would leak plasma proteins. Experimental
studies have challenged this idea and hypothesized that
albuminuria itself could damage the kidney cell [3, 6].
Although a cause-effect relationship for proteinuria and
progressive kidney damage is hard to identify clinically,
the predictive power of proteinuria or albuminuria for
progressive renal insufficiency has been demonstrated
in patients with nondiabetic and diabetic renal disease
[33, 34]. The risk appears to be independent of other es-
tablished risk markers, such as hypertension and hyper-
glycemia in the diabetic setting [35]. Among a series of
baseline parameters, proteinuria was a strong and inde-
pendent predictor of renal outcome in 409 patients with
insulin-dependent diabetes and nephropathy [36], and in
a series of 840 patients with nondiabetic renal disease en-
tering the Modification of Diet in Renal Disease study
(MDRD) [37]. In a longitudinal study [38], we followed
274 patients with nondiabetic chronic nephropathies and
clinical proteinuria, and found the only baseline variable
that correlated significantly with decline in GFR and pro-
gression of disease to end-stage renal failure was urinary
protein excretion. Analysis of the Ramipril Efficacy in
Nephropathy (REIN) study, on the other hand, supports
the assertion that the renal protection conferred by ACE
inhibitors exceeds the agents’ antihypertensive action
[38]. The finding that ramipril-induced reduction in uri-
nary protein excretion rate was the only time-dependent
covariate that predicted a lower rate of GFR decline, and
progression to ESRD indicated clearly that renoprotec-
tion is linked to reduction of protein traffic. More recent
observations from the RENAAL trial have confirmed
these findings, and showed that albuminuria is the most
powerful marker for subsequent renal events even in type
2 diabetic patients [39]. The antiproteinuric effect of the
angiotensin II type 1 receptor blocker losartan appeared
to explain most of the renoprotection conferred by this
agent, and was beyond that which could be attributed
to the drug effect on blood pressure. Moreover, the de-
gree of residual albuminuria did remain proportionally
associated with renal risk. Thus, suppressing albuminuria
is associated with a reduction in risk, and it is predicted
that additional suppression of albuminuria would be as-
sociated with additional end-organ protection.
CONCLUSION
In several studies, the increase in urinary protein excre-
tion correlated with the tendency of the renal disease to
progress more than with the underlying renal disease it-
self. Whenever urinary protein excretion is reduced, the
decline in the glomerular filtration rate slows or stops.
Interstitial inflammation and progression of disease can
be effectively limited by drugs that, by ameliorating the
glomerular perm-selective barrier to proteins, limit both
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proteinuria and filtered protein-dependent signaling for
mononuclear cell infiltration and extracellular matrix de-
position. Thus, new evidence from both experimental and
clinical data strongly suggests that therapeutic interven-
tions aimed to decrease protein loading of the proximal
tubular cells can effectively limit the progressive de-
cline in the glomerular filtration rate and progression to
end-stage renal disease. As with blood pressure, therapy
strategies should be, therefore, guided with the sole aim
to reduce proteinuria/albuminuria to the lowest achiev-
able level.
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